 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Dec 21, 2010 |
| Title |
Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Attenuated poxviruses are safe and capable to express foreign antigens. Poxviruses are applied in veterinary vaccination and explored as candidate vaccines for humans. However, poxviruses express multiple genes encoding proteins that interfere with components of the innate and adaptive immune response. This manuscript describes two strategies aimed to improve the immunogenicity of the highly attenuated, host-range restricted poxvirus NYVAC: deletion of the viral gene encoding type-I interferon-binding protein and development of attenuated replication-competent NYVAC. We evaluated these newly generated NYVAC mutants, encoding HIV-1 env, gag, pol and nef, for their ability to stimulate HIV-specific CD8 T-cell responses from blood mononuclear cells of HIV-infected subjects. The new vectors were evaluated and compared to the parental NYVAC vector in dendritic cells (DCs), RNA expression arrays, HIV gag expression and direct and cross-presentation assays in vitro. Deletion of type-I interferon-binding protein enhanced expression of interferon and interferon-induced genes in DCs, and increased maturation of infected DCs. Restoration of replication competence induced activation of pathways involving antigen processing and presentation. Also, replication-competent NYVAC showed increased Gag expression in infected cells, permitting enhanced cross-presentation to HIV-specific CD8 T cells and proliferation of HIV-specific memory CD8 T-cells. The recombinant NYVAC combining both modifications induced interferon-induced genes and genes involved in antigen processing and presentation, as well as increased Gag expression. This combined replication-competent NYVAC is a promising candidate for the next generation of HIV vaccines.
|
| |
|
| Overall design |
RNA expression obtained from DCs infected by NYVAC-C-dB19R and NYVAC-C-KC-dB19R compared to RNA expression obtained from DCs infected by NYVAC-C
Supplementary file 'normalized_data_Human_V3_V2.txt' reports data for ILMN identifiers common to platforms HumanRef8V2 and HumanRef8V3.
|
| |
|
| Contributor(s) |
Quakkelaar ED, Redeker A, Haddad EK, Harari A, McCaughey SM, Duhen T, Filali-Mouhim A, Goulet J, Loof NM, Ossendorp F, Perdiguero B, Heinen P, Gomez CE, Kibler K, Koelle DM, Sékaly RP, Sallusto F, Lanzavecchia A, Pantaleo G, Esteban M, Tartaglia J, Jacobs B, Melief CJ |
| Citation(s) |
21347234 |
| Submission date |
Dec 21, 2010 |
| Last update date |
Mar 20, 2017 |
| Contact name |
Ali Filali |
| E-mail(s) |
afilali@vgtifl.org
|
| Organization name |
Vaccine & Gene Therapy Institute of Florida
|
| Street address |
11350 SW Village Parkway, 3rd Floor
|
| City |
port st-lucie |
| State/province |
Florida |
| ZIP/Postal code |
34987 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL6104 |
Illumina humanRef-8 v2.0 expression beadchip |
| GPL6883 |
Illumina HumanRef-8 v3.0 expression beadchip |
|
| Samples (80)
|
|
| Relations |
| BioProject |
PRJNA135065 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE26239_Illumina_Human_V3_V2_probe_mapping_file_2008-02-13.txt.gz |
1.3 Mb |
(ftp)(http) |
TXT |
| GSE26239_RAW.tar |
7.4 Mb |
(http)(custom) |
TAR |
| GSE26239_non-normalized_data_HumanRef8V2.txt.gz |
3.3 Mb |
(ftp)(http) |
TXT |
| GSE26239_non-normalized_data_HumanRef8V3.txt.gz |
4.1 Mb |
(ftp)(http) |
TXT |
| GSE26239_normalized_data_Human_V3_V2.txt.gz |
6.1 Mb |
(ftp)(http) |
TXT |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...